As previously reported, Exane BNP Paribas upgraded Healthpeak Properties to Outperform from Neutral with a price target of $21, up from $19, after the company boosted its FY24 adjusted funds from operations, or AFFO, per share forecast. While acknowledging that conditions remain challenging for life science given the large amount of new supply, the analyst believes that the current price of shares is “more than adequately pricing in this uncertainty.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties Q1 2024 Financial Results Released
- Healthpeak Properties resumed with a Buy at Mizuho
- Crocs initiated, Bill downgraded: Wall Street’s top analyst calls
- Healthpeak Properties upgraded to Buy from Underperform at BofA
- Healthpeak Properties price target raised to $26 from $22 at Baird
